Umbilical Mesenchymal Stromal Cells as Cellular Immunotherapy for Septic Shock

Recruiting Phase 2 Interventional Study
Septic Shock Sepsis Pathologic Processes Shock Systemic Inflammatory Response Syndrome Inflammation Infections
Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Trial phase
Phase 2
Study type
Interventional
Purpose
Treatment
Participants needed
296 (estimated)
Sponsor
Ottawa Hospital Research Institute · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Septic shock is associated with substantial burden in terms of both mortality and morbidity for survivors of this illness. Pre-clinical sepsis studies suggest that mesenchymal stem (stromal) cells (MSCs) modulate inflammation, enhance pathogen clearance and tissue repair and reduce death. Our team has completed a Phase I dose escalation and safety clinical trial that evaluated MSCs in patients wit…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: A participant must meet all the following inclusion criteria at time of randomization to be eligible: 1. At least 18 years of age AND 2. Requirement for admission to the intensive care unit AND 3. Index admission to the intensive care unit AND 4. Cardiovascular organ failure fo…
Contacts

Josee Champagne

613-737-8899

UCCISS@ohri.ca

CONTACT